Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) released its financial results for the first quarter of 2025, alongside updates on its expanding immuno-inflammatory (I&I) pipeline and leadership changes. The …
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has named Jesse Hall, M.D., as its new Chief Medical Officer. Dr. Hall brings decades of expertise in medical and clinical development, …
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ATI-052, a bispecific …
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its participation in two scheduled healthcare conferences in March 2025, where the company’s leadership team will provide insights into its …
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its fourth quarter and full-year 2024 financial results, along with key pipeline advancements and corporate updates signaling a pivotal year ahead.
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug that acts as a covalent inhibitor of two key immune signaling kinases, ITK …
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the creation of its new Scientific Advisory Board (SAB), marking a strategic step in advancing its focus on immuno-inflammatory diseases. The …
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has taken bold steps to secure top talent by granting stock options and restricted stock units (RSUs) under its 2024 Inducement Plan. On …
Aclaris Therapeutics Awards Stock Options to Attract Top Talent Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has granted stock options and restricted stock units (RSUs) to multiple new employees, including its recently appointed President and Chief Operating Officer, …
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has entered into an exclusive licensing agreement with Biosion, Inc., securing worldwide rights, excluding Greater China, to two promising antibody therapies. This …
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies Read More